Akeso's Cadonilimab Shows Near-Complete Remission in Advanced Cervical Cancer
Event summary
- Akeso's cadonilimab demonstrated a 100% 24-month overall survival (OS) rate in patients with recurrent/metastatic cervical cancer (R/M CC) who achieved a complete response (CR) in a Phase II clinical trial.
- The study, presented at ESGO 2026, included 99 efficacy-evaluable patients, with a median follow-up of 26.5 months.
- Cadonilimab’s median progression-free survival (PFS) in CR patients was not reached, with a 12-month PFS rate of 84.6%.
- The drug is already approved in China for first-line gastric cancer, first-line cervical cancer, and recurrent/metastatic cervical cancer.
The big picture
Akeso’s cadonilimab represents a significant advancement in immunotherapy for cervical cancer, a disease with limited treatment options and poor prognosis. The near-complete remission observed in CR patients suggests a potential paradigm shift in treatment approaches, particularly for patients who have failed prior platinum-based chemotherapy. This success underscores the growing importance of bispecific antibodies and ‘IO 2.0’ strategies that overcome limitations of existing checkpoint inhibitors.
What we're watching
- Regulatory Approval
- The exceptional survival data will likely accelerate cadonilimab’s regulatory review in other markets, but acceptance will hinge on replicating these results in larger, global trials.
- Commercial Adoption
- The drug’s success will depend on clinicians’ willingness to adopt a novel bispecific antibody, particularly given existing standard-of-care treatments.
- Pipeline Expansion
- Akeso’s strategy of expanding cadonilimab’s indications across various cancer types and treatment settings will determine the drug’s long-term revenue potential.
Related topics